2-47800798-C-T
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PM2PP5_Very_Strong
The NM_000179.3(MSH6):c.2815C>T(p.Gln939*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (★★★). Variant results in nonsense mediated mRNA decay.
Frequency
Consequence
NM_000179.3 stop_gained
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 18 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 34
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Lynch syndrome 5 Pathogenic:1
This variant is considered pathogenic. This variant creates a termination codon and is predicted to result in premature protein truncation. -
Lynch syndrome Pathogenic:1
Coding sequence variation resulting in a stop codon -
Hereditary nonpolyposis colorectal neoplasms Pathogenic:1
This sequence change creates a premature translational stop signal (p.Gln939*) in the MSH6 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in MSH6 are known to be pathogenic (PMID: 18269114, 24362816). This variant is not present in population databases (gnomAD no frequency). This premature translational stop signal has been observed in individual(s) with colorectal cancer and/or endometrial cancer (PMID: 17117178, 26517685). ClinVar contains an entry for this variant (Variation ID: 89318). For these reasons, this variant has been classified as Pathogenic. -
Hereditary cancer-predisposing syndrome Pathogenic:1
The p.Q939* pathogenic mutation (also known as c.2815C>T), located in coding exon 4 of the MSH6 gene, results from a C to T substitution at nucleotide position 2851. This changes the amino acid from a glutamine to a stop codon within coding exon 4. This mutation was detected in an individual diagnosed with colon cancer at age 47 who had a family history of colon cancer (Kets CM et al. Br J Cancer. 2006 Dec 18;95(12):1678-82) as well as in an individual with endometrioid endometrial cancer diagnosed at age 60 (Jóri B et al. Oncotarget, 2015 Dec;6:41108-22). This mutation was also detected in an individual diagnosed with colon cancer at ages 38, 51, 58 followed by cancer of the ileum at age 65 and urothelial cancer at age 69. The ileum tumor showed microsatellite instability and a loss of MSH6 staining on IHC. This individual also had a family history of HNPCC associated cancers (Overbeek LI et al. Br J Cancer. 2007 May 21;96(10):1605-12). In another study, this variant was reported in 1/60,466 breast cancer cases and in 0/53,461 controls (Dorling et al. N Engl J Med, 2021 02;384:428-439). In addition to the clinical data presented in the literature, this alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. As such, this alteration is interpreted as a disease-causing mutation. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at